Rock Springs Capital
Baltimore, Maryland, United StatesFounded 2013
Rock Springs Capital is a specialist healthcare investment firm managing approximately $1.8B across two strategies. Founded in 2013 by Kris Jenner and Mark Bussard, the firm uses a research-intensive, science-first approach to identify transformative healthcare opportunities, primarily through long-biased public equity investments in biotechnology, pharmaceuticals, and medical device companies.
40% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (3 deals in the last 12 months vs 7 prior). Their most common stage is series-b (40% of deals). Average disclosed round size is $131.3M (across 105 rounds with reported amounts).
Portfolio
92
Fund Size
$1.8B
Top Stage
Series B
Last 12 Mo
3
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
124 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 City Therapeutics | Series B | $99.5M | Jun 2026 |
| HHemab | Series C | $157M | Oct 2025 |
 Treeline Biosciences | Series A | — | Sep 2025 |
 Avalyn Pharma, Inc. | Series D | $100M | Jul 2025 |
 Latigo Biotherapeutics | Series B | $150M | Mar 2025 |
 Reneo | Series B | $47.3M | Feb 2025 |
| HHemab | Series C | $157M | Jan 2025 |
 SwiftConnect | Series B | $37M | Nov 2024 |
| City Therapeutics | Series A | — | Oct 2024 |
 ArsenalBio | Unknown | $325M | Sep 2024 |
| ArsenalBio | Series C | $325M | Sep 2024 |
 Zenas BioPharma | Series C | $200M | May 2024 |
 Leap Therapeutics | Series B | $40M | Apr 2024 |
 Overjet | Series C | $53.2M | Mar 2024 |
 Apollo Therapeutics | Series C | $226.5M | Jan 2024 |
| Zenas BioPharma | Series C | $200M | Jan 2024 |
| AArsenal Biosciences | Series C | $325M | Jan 2024 |
| Avalyn Pharma, Inc. | Series C | $175M | Sep 2023 |
| AAvalyn | Series C | $100M | Sep 2023 |
| GGenesis Therapeutics | Seed | $200M | Aug 2023 |
| AAeglea Biotherapeutics | Bridge | — | Aug 2023 |
| HHemab Therapeutics Holdings | Series B | $135M | Feb 2023 |
| HHemab | Series B | $135M | Feb 2023 |
 Vigil Neuroscience | Series B | $90M | Jan 2023 |
| Avalyn Pharma, Inc. | Series C | $175M | Jan 2023 |
Page 1 of 5
Top Co-Investors
OrbiMed27 shared
T. Rowe Price26 shared
RA Capital Management25 shared
Cormorant Asset Management22 shared
Surveyor Capital19 shared
Samsara BioCapital18 shared
Novo Capital18 shared
Sofinnova Partners17 shared
Wellington Management15 shared
Perceptive Advisors15 shared
SR One14 shared
Novo Holdings A/S14 shared
HBM Healthcare Investments14 shared
New Enterprise Associates14 shared
The Invus Group, LLC13 shared
F-Prime Capital12 shared
RiverVest Venture Partners12 shared
Pivotal Life Sciences12 shared
Northpond Ventures12 shared
Andreessen Horowitz12 shared
Last updated: 7 October 2026